SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

The December 2023 quarter revenue stood at Rs. 50737.50 millions, up 9.21% as compared to Rs. 46457.50 millions during the corresponding quarter last year.A comparatively good net profit growth of 48.20% to Rs. 7213.10 millions was reported for the quarter ended December 2023 compared to Rs. 4867.30 millions of previous same quarter.The company reported a good operating profit of 14358.00 millions compared to 10674.10 millions of corresponding previous quarter.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202312 202212 % Var 202312 202212 % Var 202303 202203 % Var
Sales 50737.50 46457.50 9.21 146360.30 148639.20 -1.53 208121.40 155859.80 33.53
Other Income 2284.80 746.30 206.15 5079.50 2925.50 73.63 3292.90 11968.80 -72.49
PBIDT 14358.00 10674.10 34.51 40409.60 42709.40 -5.38 67518.90 38654.40 74.67
Interest 2149.20 1308.90 64.20 5664.90 3107.30 82.31 4721.80 3881.00 21.66
PBDT 11510.70 9365.20 22.91 32554.50 39602.10 -17.80 33419.20 16568.10 101.71
Depreciation 3996.00 4304.40 -7.16 12075.80 11888.90 1.57 16008.70 13499.50 18.59
PBT 7514.70 5060.80 48.49 20478.70 27713.20 -26.10 17410.50 3068.60 467.38
TAX 301.60 193.50 55.87 572.90 597.80 -4.17 503.30 4068.50 -87.63
Deferred Tax 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
PAT 7213.10 4867.30 48.20 19905.80 27115.40 -26.59 16907.20 -999.90 -1790.89
Equity 2399.30 2399.30 0.00 2399.30 2399.30 0.00 2399.30 2399.30 0.00
PBIDTM(%) 28.30 22.98 23.17 27.61 28.73 -3.91 32.44 24.80 30.81

Sun Pharma Inds. Share Price

1675.20 -17.95 (-1.06%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×